Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles

Will oversee launch of new medicines and Otsuka partnership respectively

Danish pharma firm Lundbeck has promoted Andreas Eggert to senior VP for global product strategy and Klaus Abel to VP with responsibility for commercialisation of medicines from Lundbeck's partnership with Otsuka Pharmaceuticals.

Eggert, who joined Lundbeck in 2010 as VP for global product strategy, will have overall responsibility for the launches of several new medicines from Lundbeck during the next 18 months, including vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence.

Prior to joining Lundbeck, Eggert spent several years at Wyeth (now part of Pfizer) where his roles included serving as director global strategic marketing and VP and global business manager.

Andreas Eggert - LundbeckKlaus Abel - Lundbeck
Andreas Eggert and Klaus Abel

Abel's responsibilities will cover the collaborative development and commercialisation of medicines Lundbeck is working on with Otsuka as part of a multi-billion dollar deal, including a once-monthly aripiprazole formulation for the treatment of schizophrenia and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major depression.

Abel, who has been with Lundbeck since 2000, and was most recently executive director with commercial responsibility for several products, will report to Eggert who will in turn report directly to president and CEO Ulf Wiinberg.

23rd August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics